EYPT EYEPOINT PHARMACEUTICALS INC Other Situations 8-K Filing 2023 - Interim Safety Data Announcement EyePoint Pharmaceuticals announced interim safety data and patient characteristics for the DAVIO 2 Clinical Trial at the OIS Retina Innovation Summit.Get access to all SEC 8-K filings of the EYEPOINT PHARMACEUTICALS INC